Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension of CRAD001H2304: Long-term everolimus in liver transplant recipients
2009-017311-15Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus in Hepatic transplant rejection (LTR) and acute liver rejection (ACR), sponsored by Novartis. Primary endpoint: Renal function at Month 36 post-transplantation. Started Feb 2010; status: completed.
02
Drugs
everolimus
03
Conditions
Hepatic transplant rejection (LTR)acute liver rejection (ACR)
Beyond the preview
Go deeper on 2009-017311-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017311-15.